QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruppert, S Articles by Schütz, G Search for Related Content PubMed PubMed Citation Articles by Ruppert, S Articles by Schütz, G Social Bookmarking                   What's this?

Research Papers

Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice.

Institute of Cell and Tumor Biology, German Cancer Research Center, Heidelberg.

Abstract

Mice homozygous for albino deletions encompassing the locus alf/hsdr-1 die shortly after birth. Lethality is thought to be the consequence of hypoglycemia, which results from the failure to activate hormone-dependent genes in liver and kidney encoding enzymes important for gluconeogenesis. Within the region in which alf/hsdr-1 has been defined by physical mapping, we identified the gene encoding fumarylacetoacetate hydrolase (FAH), an enzyme of tyrosine metabolism. Lack of FAH activity should lead to accumulation of toxic tyrosine metabolites. In man, genetically determined FAH deficiency is the primary defect in tyrosinemia type I, a fatal liver disease of infants. Northern blot and in situ hybridization analysis of mouse tissues showed that the cell types that normally express FAH correspond to those that exhibit a phenotype in alf/hsdr-1 deletion mice. Moreover, we could mimic aspects of the alf/hsdr-1 deletion phenotype in vitro by treating primary hepatocyte cultures with an intermediate of tyrosine metabolism. These findings strongly suggest that alf/hsdr-1 encodes FAH and that absence of FAH is responsible for neonatal lethality in albino deletion mice. Mechanisms by which this metabolic defect might bring about alterations in gene expression characteristic of the alf/hsdr-1 deletion phenotype are discussed.

CiteULike

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				K. Nakamura, Y. Tanaka, H. Mitsubuchi, and F. Endo Animal Models of Tyrosinemia J. Nutr., June 1, 2007; 137(6): 1556S - 1560S. [Abstract] [Full Text] [PDF]

				F. Endo, Y. Tanaka, K. Tomoeda, A. Tanoue, G. Tsujimoto, and K. Nakamura Animal Models Reveal Pathophysiologies of Tyrosinemias J. Nutr., June 1, 2003; 133(6): 2063S - 2067. [Abstract] [Full Text] [PDF]

				X. Wang, E. Montini, M. Al-Dhalimy, E. Lagasse, M. Finegold, and M. Grompe Kinetics of Liver Repopulation after Bone Marrow Transplantation Am. J. Pathol., August 1, 2002; 161(2): 565 - 574. [Abstract] [Full Text] [PDF]

				R. Jorquera and R. M. Tanguay Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability Hum. Mol. Genet., August 1, 2001; 10(17): 1741 - 1752. [Abstract] [Full Text] [PDF]

				J. L. Aponte, G. A. Sega, L. J. Hauser, M. S. Dhar, C. M. Withrow, D. A. Carpenter, E. M. Rinchik, C. T. Culiat, and D. K. Johnson Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1 PNAS, January 16, 2001; 98(2): 641 - 645. [Abstract] [Full Text] [PDF]

				M.-S. SUN, S. HATTORI, S. KUBO, H. AWATA, I. MATSUDA, and F. ENDO A Mouse Model of Renal Tubular Injury of Tyrosinemia Type 1: Development of de Toni Fanconi Syndrome and Apoptosis of Renal TubularCells in Fah/Hpd Double Mutant Mice J. Am. Soc. Nephrol., February 1, 2000; 11(2): 291 - 300. [Abstract] [Full Text] [PDF]

				R. JORQUERA and R. M. TANGUAY Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis FASEB J, December 1, 1999; 13(15): 2284 - 2298. [Abstract] [Full Text]

				S. Kubo, M. Sun, M. Miyahara, K. Umeyama, K.-i. Urakami, T. Yamamoto, C. Jakobs, I. Matsuda, and F. Endo Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors PNAS, August 4, 1998; 95(16): 9552 - 9557. [Abstract] [Full Text] [PDF]

				F. Endo, S. Kubo, H. Awata, K. Kiwaki, H. Katoh, Y. Kanegae, I. Saito, J.-i. Miyazaki, T. Yamamoto, C. Jakobs, et al. Complete Rescue of Lethal Albino c14CoS Mice by Null Mutation of 4-Hydroxyphenylpyruvate Dioxygenase and Induction of Apoptosis of Hepatocytes in These Mice by in Vivo Retrieval of the Tyrosine Catabolic Pathway J. Biol. Chem., September 26, 1997; 272(39): 24426 - 24432. [Abstract] [Full Text] [PDF]

				G Kelsey, S Ruppert, F Beermann, C Grund, R M Tanguay, and G Schutz Rescue of mice homozygous for lethal albino deletions: implications for an animal model for the human liver disease tyrosinemia type 1. Genes & Dev., December 1, 1993; 7(12a): 2285 - 2297. [Abstract] [PDF]

				M Grompe, M al-Dhalimy, M Finegold, C N Ou, T Burlingame, N G Kennaway, and P Soriano Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes & Dev., December 1, 1993; 7(12a): 2298 - 2307. [Abstract] [PDF]

				S. Goss A fresh look at the somatic cell genetics of hepatoma differentiation J. Cell Sci., January 2, 1993; 104(2): 231 - 235. [PDF]

				R. L. Bateman, P. Bhanumoorthy, J. F. Witte, R. W. McClard, M. Grompe, and D. E. Timm Mechanistic Inferences from the Crystal Structure of Fumarylacetoacetate Hydrolase with a Bound Phosphorus-based Inhibitor J. Biol. Chem., April 27, 2001; 276(18): 15284 - 15291. [Abstract] [Full Text] [PDF]